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1Introduction
A family history of breast cancer (BC) is a known risk 
factor for the onset of disease [1], with an increased risk 
depending on the degree of family history [2, 3]. However, 
the link between family history and severity at time of diag-
nosis is less well described. Further clarification of this asso-
ciation could help the implementation of appropriate 
guidelines for clinicians and patients, with regards to screening, 
diagnosis and treatment. The association between family 
history and BC severity is unclear, and existing literature is 
scarce. A study of 2256 BC patients with invasive operable 
BC concluded that patients with a family history had smaller 
tumors that were more likely to be estrogen receptor (ER) 
positive [4]. However, a Swedish population- based registry 
study found a nonsignificant improved prognosis in women 
with a family history of BC [5]. Additionally, the association 
between family history and BC- specific mortality is not well 
defined. A review by the Collaborative Group on Hormonal 
Factors in Breast Cancer, constituting 52 studies, did not 
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Abstract
A family history (FH) of breast cancer (BC) is known to increase an individual’s 
risk of disease onset. However, its role in disease severity and mortality is less 
clear. We aimed to ascertain associations between FH of BC, severity and BC- 
specific mortality in a hospital- based cohort of 5354 women with prospective 
information on FH. We included women diagnosed at Guy’s and St Thomas’ 
NHS Foundation Trust between 1975 and 2012 (n = 5354). BC severity was 
defined and categorized as good, moderate, and poor prognosis. Data on BC- 
specific mortality was obtained from the National Cancer Registry and medical 
records. Associations between FH and disease severity or BC- specific mortality 
were evaluated using proportional odds models and Cox proportional hazard 
regression models, respectively. Available data allowed adjustment for potential 
confounders (e.g., treatment, socioeconomic status, and ethnicity). FH of any 
degree was not associated with disease severity at time of diagnosis (adjusted 
proportional OR: 1.00 [95% CI: 0.85 to 1.17]), which remained true also after 
stratification by period of diagnosis. FH of BC was not associated with BC- 
mortality HR: 0.99 (95% CI: 0.93 to 1.05). We did not find evidence to support 
an association between FH of BC and severity and BC- specific mortality. Our 
results indicate that clinical management should not differ between women with 
and without FH, when the underlying mutation is unknown.
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find an association between family history and BC- mortality 
[6] along with several others [7–12], whereas other studies 
have found a positive or even an inverse association [5, 
13–20]. One study of over 1200 young women (defined as 
those diagnosed before the age of 45 years) with invasive 
BC found that women with no family history had a reduced 
BC- mortality. Interestingly, women with a first degree rela-
tion showed a 40% reduction in mortality risk, whereas 
women with only a second degree relation experienced similar 
results to women with no family history [17]. On the con-
trary, another study reported no statistically significant dif-
ference between patients with a family history of BC with 
regard to the risk of mortality [8]. Some of the variation 
may be explained by the varying study designs, study popu-
lation sizes, and differences in the adjustment for confounding 
variables. Using data on 5354 BC patients from the King’s 
Health Partners Breast Cancer Biobank (KHPBCBB), we 
assessed the extent to which family history of BC was associ-
ated with BC severity and BC- specific mortality.
Methods
Study population and data collection
The King’s Health Partners Breast Cancer Biobank consists 
of over 12,000 patients, added consecutively with prospectively 
recorded data, who were treated for invasive BC at Guy’s 
Hospital, London between January 1st 1975 and December 
31st 2012. For the purposes of this study, we selected all 
women diagnosed with a primary invasive BC at Guy’s 
Hospital, with data available on their family history. Patients 
were excluded if there was no documentation of curative 
surgery being undertaken, and if consent was not obtained. 
We also excluded 18 women who were lactating or pregnant 
at time of diagnosis, 1303 women with missing data for 
family history and 205 with an unknown menstrual status 
were not included. The final cohort contained 5354 women.
The following demographic and clinical characteristics, 
recorded prospectively, were included: age (≤40, 40–49, 50–59, 
60–69 and ≥70), self- reported ethnicity (white, black, mixed, 
and other), socioeconomic status (SES) (scored as low, 
medium, high), parity (split into categories of 0, 1–2, 3–4, 
and ≥5 live births), natural menopausal status (pre, peri, and 
post), clinical tumor size (≤2 cm, 2–5 cm, and ≥5 cm), 
pathological lymph node status (none, <3, 4–10, and ≥10), 
histopathological grade, estrogen receptor, progesterone recep-
tor, and HER2 status, and systemic treatments (including 
chemotherapy, endocrine therapy or radiotherapy). 
Socioeconomic status (SES) was based on the patients’ post-
code using the ‘The English Indices of Deprivation 2010’, 
which is based on education, income, and wealth of environ-
ment. Family history was patient reported, and divided into 
first degree, second degree, first and second degree and finally, 
third degree and no history of BC. Patients with only a third 
degree of family history were grouped with those without 
any family history because evidence is limited, but the exist-
ing consensus is that the associated increased risk of BC is 
smaller in patients with only a third degree relative with a 
history of BC [1]. BC severity was defined using a modified 
version of the St Gallen criteria, as shown in Table 1 [21].
Clinical follow- up information was collected for all women 
as the hospital’s standard procedure up until the 31st 
December 2007. After 2007, low- risk women were not fol-
lowed up as per hospital protocol, but only those who 
later returned to clinic with evidence of further disease 
were followed up. Women who did not return to the clinic 
were assumed to have not experienced any disease progres-
sion and/or recurrence. All follow- up information was taken 
from medical records, which also provided information on 
cause of death, date of last contact, and date of disease 
recurrence. National death certificate information was 
obtained from the National Cancer Registry, and the Office 
of National Statistics, which were used to confirm the cause 
of death. Data collection for the purposes of this study 
was permitted under the approval of the Guy’s NHS Research 
Ethics Committee (REC Number: 12/EE/0493) for women 
diagnosed up to September 2006, for women diagnosed 
afterwards individual consent was obtained.
Statistical analysis
The association between family history and BC severity 
at the time of diagnosis was analyzed with multivariate 
proportional odds models, as the latter is an ordinal cat-
egorical outcome measurement. All models were checked 
to ensure that the proportional odds assumption held. 
As a next step, multivariate Cox proportional hazards 
models were used to assess the association between family 
history and BC- specific death. Follow- up time was defined 
from the time of diagnosis until death or last day seen. 
All models were adjusted for age at diagnosis, time period 
of diagnosis, ethnicity, SES, parity, menopausal status, 
positive nodes, tumor size, ER, PR, HER2, as well as 
primary treatment unless stated otherwise. Stratified analy-
ses were performed by time period of diagnosis (1975–1989 
or 1989–2012). This stratification aimed to capture the 
Table 1. Breast cancer (BC) severity criteria, created using a modified 
version of the St Gallen criteria [21]. 
Good Moderate Severe
ER (estrogen receptor) + or ER- 
AND
TNM Stage I
ER+, age >40 
AND
TNM Stage II
<40 years, TNM  
Stage II 
OR
ER- , TNM Stage II 
OR
TNM Stage III or IV
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Table 2. Descriptive characteristics by family history.
All BC
BC (breast cancer) with Severity 
Information No severity information
Family History 
(N = 1189) N 
(%)
No Family 
History 
(N = 4165) N 
(%) P- value
Family 
History 
(N = 791) 
(N %)
No Family 
History 
(N = 2637) 
(N %) P - value
Family 
History 
(N = 398) 
(N %)
No Family 
History 
(N = 1528) 
(N %) P - value
Age at diagnosis (years)
≤40 128 (10.77) 380 (9.12) 0.03 92 (11.63) 280 (10.62) 0.01 36 (9.05) 100 (6.54) 0.53
40–49 297 (24.98) 958 (23.00) 204 (25.79) 600 (22.75) 93 (23.37) 358 (23.43)
50–59 337 (28.34) 1142 (27.42) 232 (29.33) 726 (27.53) 105 (26.38) 416 (27.23)
60–69 264 (22.20) 986 (23.67) 182 (23.01) 249 (24.61) 82 (20.60) 337 (22.05)
≥70 163 (13.71) 699 (16.78) 81 (10.24) 382 (14.49) 82 (20.60) 317 (20.75)
Socioeconomic status 
Low 702 (59.04) 2607 (62.59) 0.02 487 (61.57) 1727 (65.49) 0.03 215 (54.02) 880 (57.59) 0.44
Medium 46 (3.87) 115 (2.76) 39 (4.93) 83 (3.15) 7 (1.76) 32 (2.09)
High 256 (21.53) 781 (18.75) 178 (22.50) 528 (20.02) 78 (19.60) 253 (16.56)
Missing 185 (15.56) 662 (15.89) 87 (11.00) 299 (11.34) 98 (24.62) 363 (23.76)
Ethnicity
White 331 (27.84) 924 (22.18) 0.0003 251 (31.73) 721 (27.34) 0.03 16 (4.02) 203 (13.29) 0.007
Black 15 (1.26) 89 (2.14) 8 (1.01) 55 (2.09) 7 (1.76) 34 (2.23)
Other 43 (3.62) 164 (3.94) 27 (3.41) 106 (4.02) 80 (20.10) 58 (3.80)
Missing 800 (67.28) 2988 (71.74) 505 (63.84) 1755 (66.55) 295 (74.12) 1233 (80.69)
Menopausal status
Pre 433 (36.42) 1459 (35.03) 0.57 305 (38.56) 959 (36.37) 0.34 128 (32.16) 500 (32.72) 0.95
Peri 94 (7.91) 315 (7.56) 61 (7.71) 184 (6.98) 33 (8.29) 131 (8.57)
Post 662 (55.68) 2391 (57.41) 425 (53.73) 1494 (56.66) 237 (59.55) 897 (58.70)
Parity
0 239 (22.27) 853 (22.88) 0.41 170 (23.48) 508 (21.45) 0.24 69 (19.77) 345 (25.37) 0.13
1–2 538 (50.14) 1878 (50.38) 364 (50.28) 1219 (51.48) 174 (49.86) 659 (48.46)
3–4 258 (24.04) 831 (22.29) 168 (23.20) 534 (22.55) 90 (25.79) 297 (21.84)
≥5 38 (3.54) 166 (4.45) 22 (3.04) 107 (4.52) 16 (4.58) 59 (4.34)
Tumor size (cm)
Unknown 11 (0.96) 32 (0.80) 0.12 0 (0.00) 1 (0.04) 0.45 11 (3.13) 31 (2.27) 0.04
≤2 647 (56.61) 2129 (53.20) 503 (63.59) 1671 (63.37) 144 (40.91) 458 (33.55)
2–5 444 (38.85) 1655 (41.35) 259 (32.74) 835 (31.66) 185 (52.56) 820 (60.07)
≥5 41 (3.59) 186 (4.65) 29 (3.67) 130 (4.93) 12 (3.41) 56 (4.10)
Number of positive lymph nodes
0 477 (51.46) 1601 (50.05) 0.61 429 (54.24) 1364 (51.73) 0.53 48 (35.29) 237 (42.17) 0.32
1–3 294 (31.72) 999 (31.23) 257 (32.49) 875 (33.18) 37 (27.21) 124 (22.06)
4–10 93 (10.03) 365 (11.41) 79 (9.99) 296 (11.22) 14 (10.29) 69 (12.28)
≥10 63 (6.80) 234 (7.31) 26 (3.29) 102 (3.87) 37 (27.21) 132 (23.49)
Invasive grade
Unknown 314 (25.41) 1184 (28.43) 0.24 92 (11.63) 320 (12.14) 0.76 222 (55.78) 864 (56.54) 0.62
Grade 1 127 (10.68) 453 (10.88) 107 (13.53) 378 (14.33) 20 (5.03) 75 (4.91)
Grade 2 420 (35.32) 1344 (32.27) 345 (43.62) 1095 (41.52) 75 (18.84) 249 (16.30)
Grade 3 328 (27.59) 1184 (28.43) 247 (31.23) 844 (32.01) 81 (20.35) 340 (22.25)
Estrogen receptor status
Negative 245 (20.61) 973 (23.36) 0.13 134 (16.94) 475 (18.01) 0.79 111 (27.89) 498 (32.59) 0.17
Positive 739 (62.15) 2485 (59.66) 629 (79.52) 2069 (78.46) 110 (27.64) 416 (27.23)
Missing 205 (17.24) 707 (16.97) 28 (3.54) 93 (76.86) 177 (44.47) 614 (40.18)
Progesterone receptor status
Negative 411 (34.57) 1545 (37.09) 0.18 285 (36.03) 997 (37.81) 0.57 126 (31.66) 548 (35.86) 0.29
Positive 565 (47.52) 1859 (44.63) 469 (59.29) 1508 (57.19) 96 (24.12) 351 (22.97)
Missing 213 (17.91) 761 (18.27) 37 (4.68) 132 (5.01) 176 (44.22) 629 (78.14)
HER2- status
Negative 486 (40.87) 1642 (39.42) 0.64 375 (47.41) 1152 (43.69) 0.17 41 (10.30) 175 (11.45) 0.16
Positive 127 (10.68) 468 (11.24) 86 (10.87) 293 (11.11) 111 (27.89) 490 (32.07)
Missing 576 (48.44) 2055 (49.34) 330 (41.72) 1192 (45.20) 246 (61.81) 863 (56.48)
(Continued)
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effects of the introduction of mammography screening 
[22]. All statistical analyses were performed with Statistical 
Analysis Systems (SAS) release 9.3 (SAS Institute, Cary, 
NC).
Results
Of the 5354 included women, 3428 (64%) had informa-
tion sufficient to categorize them by severity at time of 
diagnosis. Of these women categorized by severity, 791 
(23%) had a family history of BC: patients with only a 
first degree accounted for 428 (54%), while those with 
second degree numbered 286 (36%) and finally, first and 
second degree accounted for 77 (10%). Thus, leaving 1926 
women (36%) with either no family history of BC as 
defined by first or second. Patient characteristics of women 
with information for severity, and women without are 
shown in Table 2: there were no significant differences 
between them. Furthermore, there was no significant dif-
ference in the mean age at primary diagnosis between 
women with a family history (56.04 [SD ± 12]) and 
women without (654.52 [SD ± 11.9]).
Table 3 shows the study population’s demographics 
stratified by BC severity status. No significant differences 
were observed between women with and without a family 
history. As a next step, the association between family 
history and BC severity (at time of diagnosis) was assessed 
through proportional odds ratios (OR) (Table 4). No ORs 
observed were statistically significant. For example, when 
comparing women with any family history to women 
without family history the proportional OR was 1.00 (95% 
CI: 0.85–1.17). To investigate this association further, 
analyses were stratified by time period of diagnosis, but 
this did not alter any of the findings (Table 4).
Finally, the hazard ratio (HR) for the risk of fatal BC 
was investigated (Table 5). No association between FH- 
and BC- specific death was observed (e.g., crude model 
HR: 0.95 [95% CI: 0.90–1.01]). Similarly, the same was 
observed when varying degrees of family history were 
investigated individually (e.g., HR for women with first 
degree of family history: 0.99 (95% CI: 0.93–1.05) adjusted 
for age, ethnicity, SES, parity, menopausal status, invasive 
grade, positive nodes, tumor size, PR, ER, HER2 recep-
tors, surgery type, and adjuvant treatments).
Discussion
Given contradicting findings within the existing literature 
regarding associations between family history and both 
tumor characteristics and BC- specific death, we used our 
hospital- based cohort to investigate this further. The results 
from this study demonstrated that family history does 
not appear to have an association with BC severity at 
time of diagnosis, nor BC- mortality.
Literature indicates women with an early- onset BC with 
family history have a higher frequency of BRCA1 and 
BRCA2 compared to women without a family history [23, 
24]. Accumulating evidence has shown that different tumor 
All BC
BC (breast cancer) with Severity 
Information No severity information
Family History 
(N = 1189) N 
(%)
No Family 
History 
(N = 4165) N 
(%) P- value
Family 
History 
(N = 791) 
(N %)
No Family 
History 
(N = 2637) 
(N %) P - value
Family 
History 
(N = 398) 
(N %)
No Family 
History 
(N = 1528) 
(N %) P - value
Surgery type 
Mastectomy 656 (55.17) 2434 (58.44) 0.11 430 (54.36) 1565 (59.35) 0.03 226 (56.78) 869 (56.87) 0.99
Breast 
conservation 
532 (44.74) 1725 (41.42) 361 (45.64) 1070 (40.58) 171 (42.96) 655 (42.87)
Other surgery 1 (0.08) 6 (0.14) 0 (0.00) 2 (0.08) 1 (0.25) 4 (0.26)
Chemotherapy
Yes 270 (22.71) 828 (19.88) 0.03 194 (24.53) 598 (22.68) 0.28 76 (19.10) 230 (15.05) 0.05
No 919 (77.29) 3337 (80.12) 597 (75.47) 2039 (77.32) 322 (80.90) 1298 (84.95)
Radiotherapy 
Yes 595 (50.04) 1923 (46.17) 0.02 398 (50.32) 1216 (46.11) 0.04 197 (49.50) 707 (46.27) 0.25
No 594 (49.96) 2242 (53.83) 393 (49.68) 1421 (53.89) 201 (50.50) 821 (53.73)
Endocrine therapy
Yes 421 (35.41) 1409 (33.83) 0.31 321 (40.58) 1024 (38.83) 0.38 100 (25.13) 385 (25.20) 0.98
No 768 (64.59) 2756 (66.17) 470 (59.42) 1613 (61.17) 298 (74.87) 1143 (74.80)
BC- Death
Yes 345 (29.02) 1335 (32.05) 0.05 215 (27.18) 760 (28.82) 0.37 130 (32.66) 575 (37.63) 0.07
No 844 (70.98) 2830 (67.95) 576 (72.82) 1877 (71.18) 268 (67.34) 953 (62.37)
Table 2. (Continued).
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characteristics were identified in patients with the BRCA1 
mutation – less so in patients with the BRCA2 mutation 
- in comparison to patients without the mutation [25–30]. 
Survival advantage for BC cases with a BRCA1 mutation 
has been reported [31, 32], whereas another study found 
poor survival when the patient’s had BRCA1 mutation 
[33].
There is discrepancy in the associations between family 
history and BC prognosis reported to date. A study incor-
porating Utah’s Population Database found that women 
under the age of 50 with a family history of BC were 
statistically significantly at a greater risk of a poorer sur-
vival when compared to those women without; with a 
relative risk of 1.54 (95% CI: 0.98–2.41) for women with 
first degree relatives previously diagnosed with BC [34]. 
In contrast, a recent population- based study [35] based 
in Netherlands reported a lower risk of all- cause death 
with ≥2 first- degree relative with family history (HR 0.2; 
95% CI 0.06–1.0). Nevertheless, several studies have found 
no association between family history and BC overall 
survival [8, 36, 37]. For instance, a study based on a 
Canadian population- based familial breast cancer registry 
[38] reported that a family history of breast or ovarian 
cancer was not associated with recurrence or death. Chang 
and colleagues also reported a null association with all- 
cause death in a cohort of BC patients in the Breast 
Cancer Family Registry in Northern California, USA when 
excluding those with BRCA1 and BRCA2 mutation [8]. 
Therefore, findings from our study are also in agreement 
with the majority of existing research regarding BC- 
mortality. Of the studies demonstrating a statistical dif-
ference in mortality, most of them focused on younger 
women, and tended to have smaller study populations.
With regard to disease- free survival, recent findings 
from the UK Prospective Outcomes in Sporadic versus 
Hereditary breast cancer (POSH) suggested that there is 
no difference in disease progression between female BC 
patients with or without a family history, with a HR of 
0.89 (95% CI: 0.76–1.03) [39]. It is clinically relevant to 
know that women with a family history of BC are not 
necessarily at a greater risk. Thus, no evidence is provided 
to date to suggest that these women should be given 
treatment different to that of what current protocol 
dictates.
The strength of this hospital- based cohort is the ability 
to adjust for possible confounding. For example, adjust-
ments could be made to account for more aggressive 
treatments, or any confounding by socioeconomic status 
Table 3. Descriptive table of breast cancer prognosis (at the time of diagnosis, as defined in the methods) by family history of breast cancer as well 
as diagnosis period.
Good prognosis N (%) Moderate prognosis N (%) Poor prognosis N (%) P - value
All women with severity (N = 3428) N = 2174 N = 954 N = 300
Family history
No 1671 (76.86) (18.76%) 734 (76.94) 232 (77.33) 0.98
Yes 503 (23.14) 220 (23.06) 68 (22.67)
Degree
No 1671 (76.86) (18.76%) 734 (76.94) 232 (77.33) 0.42
st degree 270 (12.42) 129 (13.52) 29 (9.67)
First & Second degree 48 (2.21) 19 (1.99) 10 (3.33)
Second degree 185 (8.51) 72 (7.55) 29 (9.67)
Women Diagnosed ≤1989 (N = 1,766) N = 1129 N = 490 N = 147
Family history
No 889 (78.74) 377 (76.94) 116 (78.91) 0.71
Yes 240 (21.26) 113 (23.06) 31 (21.09)
Degree
No 889 (78.74) 377 (76.94) 116 (78.91) 0.59
First degree 141 (12.49) 64 (13.06) 13 (8.84)
First & Second degree 15 (1.33) 7 (1.43) 4 (2.72)
Second degree 84 (7.44) 42 (8.57) 14 (9.52)
Women diagnosed >1989 (N = 1,662) N = 153 N = 1045 N = 464
Family history
No 782 (74.83) 357 (76.94) 116 (75.82) 0.68
Yes 263 (25.17) 107 (23.06) 37 (24.18)
Degree
No 782 (74.83) 357 (76.94) 116 (75.82) 0.40
First degree 129 (12.34) 65 (14.01) 16 (10.46)
First & Second degree 33 (3.16) 12 (2.59) 6 (3.92)
Second degree 101 (9.67) 30 (6.47) 15 (9.80)
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or ethnicity. Furthermore, while the cohort is hospital 
based, it is defined by a specific catchment area so that 
the included individuals remain unselected and it is close 
to a population- based cohort. A study based largely on 
referred individuals, may have led to a bias of different 
family history. In previous studies where positive associa-
tions were observed between FH and severity or mortality 
limited adjustments for confounding were made [1, 4, 5, 
14, 18]. By contrast, studies which observed no associa-
tion between the two, as seen here, adjusted for established 
prognostic factors along with age, and race in some 
instances [8–10, 37].
Despite its large size, there are some limitations to 
consider. Firstly, patient genetics were not collected in 
our study. Thus, we cannot disentangle any effect modi-
fications by type of mutation (i.e., BRCA1). Secondly, 
approximately one- third of women in the dataset did not 
have information on BC severity recorded. However, it 
can be seen in Table 2 that the women with severity are 
representative of the entire cohort. A further limitation 
of this dataset is the incomplete data collection for some 
confounding variables, such as ER/PR/HER2 status. 
However, due to the large population and extensive follow-
 up period, it remains a valuable and informative resource. 
Another potential limitation of this dataset is the lack of 
additional information for the known risk factors of BC, 
such as age at menarche, age at first birth, obesity, and 
HRT. However, these risk factors (bar obesity) are not 
among those considered to be strong prognostic factors 
of BC and thus we deem the potential confounding influ-
ence to be low [40–42]. In terms of disease severity, a 
modified version of the St Gallen’s criteria was used where 
Table 5. Hazard ratio (HR) and 95% confidence intervals (CI) for fatal BC (breast cancer) by family history of breast cancer, in women with sufficient 
data to allow classification by severity.
Fatal Non- Fatal
HR (95% CI)1 HR (95% CI)2 HR (95% CI)3N (%)
All women (N = 6596) N = 975 N = 2453
Family history
No 760 (77.95) 1877 (76.52) 1.00 (ref) 1.00 (ref) 1.00 (ref)
Yes 215 (22.05) 576 (23.48) 0.95 (0.90–1.01) 0.97 (0.91–1.03) 0.99 (0.93–1.05)
Degree
No 760 (77.95) 1877 (76.52) 1.00 (ref) 1.00 (ref) 1.00 (ref)
First degree 108 (11.08) 320 (13.05) 0.88 (0.76–1.03) 0.91 (0.78–1.06) 0.96 (0.82–1.12)
First & Second degree 21 (2.15) 56 (2.28) 0.91 (0.64–1.29) 0.94 (0.66–1.34) 0.94 (0. 6–1.34)
Second degree 86 (8.82) 200 (8.15) 0.94 (0.78–1.13) 0.99 (0.82–1.19) 1.02 (0.85–1.23)
1Crude model.
2Adjusted for age, time period of diagnosis, ethnicity, and socioeconomic status (SES).
3Adjusted for age, time period of diagnosis, ethnicity, SES, parity, menopausal status, invasive grade, positive nodes, tumor size, PR, ER (estrogen 
receptor), HER2 receptors, surgery type and adjuvant treatments.
Table 4. Proportional odds ratios (OR) and 95% confidence intervals 
(CI) by breast cancer severity at diagnosis, for women in the GSTT data-
base, adjusted for time period of diagnosis, ethnicity, and socioeconom-
ic status.
Good, moderate or severe BC 
(breast cancer)
N (%)
Proportional OR 
(95% CI)
All women (N = 3428)
Family history
No 2637 (76.93) 1.00 (ref)
Yes 791 (23.07) 0.98 (0.84–1.16)
Degree
No 2637 (76.93) 1.00 (ref)
First degree 428 (12.49) 0.97 (0.76–1.25)
First & Second degree 77 (2.25) 0.98 (0.79–1.20)
Second degree 286 (8.34) 1.07 (0.68–1.70)
Women diagnosed ≤1989 (N = 1766)
Family history
No 1382 (78.26) 1.00 (ref)
Yes 384 (21.74) 1.06 (0.84–1.33)
Degree
No 1382 (78.26) 1.00 (ref)
First degree 218 (12.34) 1.21 (0.85–1.72)
First & Second degree 26 (1.47) 0.93 (0.69–1.26)
Second degree 140 (7.93) 1.40 (0.65–2.99)
Women diagnosed >1989 (N = 1662)
Family history
No 1255 (75.51) 1.00 (ref)
Yes 407 (24.49) 0.91 (0.72–1.15)
Degree
No 1255 (75.51) 1.00 (ref)
First degree 210 (12.64) 0.99 (0.73–1.33)
First & Second degree 51 (3.07) 0.79 (0.55–1. 13)
Second degree 146 (8.78) 0.96 (0.54–1.70)
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we incorporated information on age (above or below 
40 years at the time of diagnosis), ER status as well as 
histopathological grade. A strength here is that these ele-
ments were prospectively derived from our KHPBCBB 
database. Furthermore, while only invasive tumors were 
included, we did not stratify by individual tumor type 
due to power issues resulting from smaller numbers. 
Finally, the long- time span of recruitments could be viewed 
as a potential variable to introduce bias, however, we 
believe that by adjusting for potential confounders such 
as treatment, surgery, age and diagnosis, and the diagnosis 
period, that the potential for any influence on the  findings 
is small.
Conclusion
We did not find evidence to support an association between 
family history of BC and severity and BC- specific mortal-
ity. Our results indicate that clinical management should 
not differ between women with and without family history 
when the underlying mutation(s) is (are) unknown. The 
literature indicates that it may be different for BRCA1/2 
carriers.
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